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Tomasz Gambin,1,6 Michele Calijorne Alcino,7 Samantha Penney,1 Jorge M. Saraiva,8,9 Hanne Hove,10
Flemming Skovby,10 Hu¨lya Kayserili,11,12 Elicia Estrella,13 Anneke T. Vulto-van Silfhout,4
Marloes Steehouwer,4 Donna M. Muzny,5 V. Reid Sutton,1,14 Richard A. Gibbs,1,5
Baylor-Hopkins Center for Mendelian Genomics, James R. Lupski,1,5,14,15 Han G. Brunner,4,16
Bregje W.M. van Bon,4 and Claudia M.B. Carvalho1,7,*
Robinow syndrome is a genetically heterogeneous disorder characterized bymesomelic limb shortening, genital hypoplasia, and distinc-
tive facial features and for which both autosomal-recessive and autosomal-dominant inheritance patterns have been described. Causative
variants in the non-canonical signaling geneWNT5A underlie a subset of autosomal-dominant Robinow syndrome (DRS) cases, butmost
individuals with DRS remain without a molecular diagnosis. We performed whole-exome sequencing in four unrelated DRS-affected in-
dividuals without coding mutations in WNT5A and found heterozygous DVL1 exon 14 mutations in three of them. Targeted Sanger
sequencing in additional subjectswithDRSuncoveredDVL1 exon14mutations infive individuals, includingapair ofmonozygotic twins.
In total, six distinct frameshift mutations were found in eight subjects, and all were heterozygous truncating variants within the penul-
timate exonofDVL1. Infive families inwhichsamples fromunaffectedparentswereavailable, thevariantsweredemonstrated to represent
denovomutations.All variant alleles arepredicted to result in apremature terminationcodonwithin the last exon, escapenonsense-medi-
ated decay (NMD), andmost likely generate aC-terminally truncated proteinwith a distinct1 reading-frame terminus. Studyof the tran-
scripts extracted from affected subjects’ leukocytes confirmed expression of bothwild-type and variant alleles, supporting the hypothesis
that mutantmRNA escapes NMD. Genomic variants identified in our study suggest that truncation of the C-terminal domain of DVL1, a
protein hypothesized to have a downstream role in the Wnt-5a non-canonical pathway, is a common cause of DRS.Introduction
In 1969, Dr. Meinhard Robinow and colleagues described
an ‘‘unrecognized dwarfing syndrome’’ in one non-
consanguineous extended family with multiple affected
individuals; analysis of the family pedigree revealed an
autosomal-dominant segregation pattern with complete
penetrance.1 Clinical description of autosomal-dominant
Robinow syndrome (DRS [MIM 180700]) includes meso-
melic shortening, genital hypoplasia, dental malalign-
ment, normal intellect, and distinctive facial features
resembling a ‘‘fetal face.’’ These features include a high
and broad forehead, frontal bossing, marked hypertelorism
with midfacial hypoplasia, prominent eyes, a depressed
nasal bridge, and a short nose with anteverted nares and
a broad tip1–3 and are collectively referred to as fetal face
because the proportion of the neurocranium to the face
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thirds face. Heterozygous missense mutations in WNT5A
(MIM 164975), which encodes a protein that participates
in the non-canonical, b-catenin-independent signaling
cascade, were later shown to segregate in the first described
family.4 Such mutations most likely change Wnt-5a sur-
face structure and affect interactions with other proteins
in the same pathway.5 In that same study, an additional
unrelated individual with sporadic DRS was also shown
to be a carrier of a distinct heterozygous mutation in
WNT5A.4 Wnt5a-null mice exhibit phenotypic features
similar to those observed in subjects with DRS, including
hypertelorism, a triangular mouth, micrognathia, and
hypoplastic genitalia.4,6,7 Autosomal-recessive Robinow
syndrome (RRS [MIM 268310]) is characterized by short
stature and pronounced mesomelic shortening and verte-
bral anomalies3,8,9 and is associated with loss-of-function
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of the orphan tyrosine kinase receptor ROR2 (MIM
602337).10,11 ROR2 is a putative receptor of Wnt-5a,12
and together they activate the non-canonical Wnt
signaling cascade, which results in the establishment of
planar cell polarity in Drosophila and in the equivalent
convergent-extension movements during gastrulation in
vertebrates.13,14 Importantly, heterozygous mutations
that truncate ROR2 around the tyrosine kinase domain
cause a distinct disease known as autosomal-dominant bra-
chydactyly type B1 (BDB1 [MIM 113000]), most likely as a
result of a gain-of-function or dominant-negative effect of
the truncating protein variant.15,16
Here, we report eight individuals with six distinct frame-
shift mutations clustered in the same exon of DVL1 (MIM
601365).DVL1 encodes one out of three human homologs
of the Drosophila segment polarity protein dishevelled
(dsh). All six variants are predicted by conceptual transla-
tion to produce a truncated protein. This contention is
supported by experimental detection of the expression of
the premature termination codon (PTC)-containing
mRNA in subject cells. Our data support the concept that
mutations involving additional proteins in the Wnt-5a-
ROR2 signaling pathway can cause Robinow syndrome.17
Furthermore, in contrast with the type of genetic alteration
reported to cause WNT5A and ROR2 disease-associated
mutations, variants in DVL1 seem to result in dominant-
negative or gain-of-function proteins.Subjects and Methods
Subjects
Phase 1 of our study consisted of candidate-gene discovery in four
affected individuals (BAB4073, BAB4569, BAB4878, and BAB5264)
with clinical diagnoses of Robinow syndrome and in both parents
of each individual (except for BAB5264, for whom only maternal
DNA was available for study); all affected subjects underwent per-
sonal genome studies using whole-exome sequencing (WES).
Phase 2 of our study consisted of confirming and assessing the
contribution of DVL1 variants in exon 14 to the disease pheno-
type. Phase 2 included 62 additional subjects, each with a clinical
suspicion of Robinow syndrome.We did not pre-select for possible
dominant or recessive inheritance. Targeted sequencing identified
mutations in five individuals (016462, 016516, 016517, 017604,
and 030526) from four families, including a monozygotic twin
pair (016516 and 016517) about whom a clinical description
was previously published.18 All five phase 2 subjects were included
in the study by Radboud University Medical Center in Nijmegen,
the Netherlands. The subjects’ countries of origin included
Portugal (016516 and 016517), Turkey (017604), the United
States (BAB4073, BAB4569, BAB4878, BAB5264, and 030526),
and Denmark (016462). Clinical findings are shown in Table 1
(see Supplemental Data for clinical descriptions). DNA was ob-
tained from the subjects and their families after they gave written
informed consent. Selected family pedigrees and photographs
of individuals who gave consent for these photos to be used are
shown in Figure 1 and Figures S1 and S2. The study was approved
by the Radboud University Medical Center review board and by
the institutional review board at the Baylor College of MedicineThe Am(protocol no. H-29697) for all sequencing conducted at the Baylor
College of Medicine Human Genome Sequencing Center (BCM-
HGSC).
WES, Variant Calling, and Selection of De Novo
Variants
DNAs from individuals BAB4073, BAB4569, BAB4878, and
BAB5264 were subjected to WES at the BCM-HGSC through the
Baylor-Hopkins Center for Mendelian Genomics initiative. With
1 mg of DNA, an Illumina paired-end pre-capture library was con-
structed according to the manufacturer’s protocol (Illumina Multi-
plexing_SamplePrep_Guide_1005361_D) with modifications as
described in the BCM-HGSC Illumina Barcoded Paired-End
Capture Library Preparation protocol. Four pre-captured libraries
were pooled and then hybridized in solution according to the
BCM-HGSC in-house CORE design19 (52 Mb, NimbleGen) and
the manufacturer’s protocol (NimbleGen SeqCap EZ Exome
Library SR User’s Guide version 2.2) with minor revisions. The
sequencing run was performed in paired-end mode with the Illu-
mina HiSeq 2000 platform; sequencing-by-synthesis reactions
were extended for 101 cycles from each end and an additional
seven cycles for the index read. With a sequencing yield of 9.9
Gb on average, all samples achieved 89% of the targeted exome
bases covered to a depth of 203 or greater. Illumina sequence anal-
ysis was performed with the BCM-HGSC Mercury analysis pipe-
line,20,21 which moves data from the initial sequence generation
on the instrument to annotated variant calls (SNPs and intra-
read indels) via various analysis tools. We identified de novo mu-
tations in silico by subtracting variants observed in either parent.
Candidate variants were filtered against exome data in publicly
available databases, including the 1000 Genomes Project, the
NHBLI Exome Sequencing Project (ESP) Exome Variant Server,
the Atherosclerosis Risk in Communities Study (ARIC) database,
and our in-house-generated database of more than 4,282 exomes.
Variant Confirmation
We verified and evaluated potential disease-associated variants
identified viaWES for co-segregation with the phenotype by using
standard PCR amplification. The primers we used to amplify exon
14 of DVL1 were as follows: 50-GGGGAAGGGCAGGTAGGG-30
(forward) and 50-CAGTGAGTGGGGGCTTCG-30 (reverse). PCR
products were purified with ExoSAP-IT (Affymetrix) and
sequenced with di-deoxy nucleotide Sanger sequencing at the
DNA Sequencing and Gene Vector Core at Baylor College of
Medicine. To confirm each frameshift individually, we manually
cloned both alleles into a standard TOPO TA cloning vector (Life
Technologies) and then transformed the recombinant clones
into chemically competent E. coli to be grown overnight; individ-
ual clonal colonies were sequenced by a standard Sanger capillary
protocol.
RNA Analysis
We extracted total RNA from peripheral blood from BAB5265,
BAB5264, BAB4073, BAB4074, and BAB4075 by using the
PAXgene Blood RNA System (PreAnalytiX). Blood was collected
and transported in PAXgene Blood RNA Tubes. RNAwas manually
extracted according to the PAXgene Blood RNA purification
protocol. cDNA was synthesized with 1 mg of RNA and the qScript
cDNA SuperMix (Quanta Biosciences). 2 ml of cDNA was used
for amplifying the mRNA fragment with primers in DVL1 exon
13 (50-TGCTACTACGTCTTCGGGGA-30 [forward]) and exon 15erican Journal of Human Genetics 96, 612–622, April 2, 2015 613
Table 1. Summary of Clinical Features of DRS-Affected Individuals in This Study
Individual
BAB4073 BAB4878 BAB5264 016462 016516 016517 017604 030526
Current age 11 years 22 years 6 years 20 years 21 years 21 years 15 years,
6 months
42 years
Age at last examination 9 years 20 years 28 months 20 years 21 years 21 years 15 years,
6 months
18 years
Genotype c.1570_1571delins c.1505_1517del c.1519del c.1505_1517del c.1508del c.1508del c.1615del c.1529del
De novo þ þ ND þ þ þ þ ND
Gender F F M F M M M F
Growth
Height percentile 10% 17% <3% 70% 90% 75% 80% <3%
Occipitofrontal
circumference SD
þ4 SDs þ2.5 SDs >þ2 SDs >þ4 SDs >þ4 SDs >þ4 SDs >þ4SDs >þ6 SDs
Facial Features
Macrocephaly þ þ þ þ þ þ þ þ
Frontal bossing þ þ þ þ þ þ þ þ
High forehead þ þ þ þ þ þ þ þ
Midface hypoplasia þ þ þ þ þ þ þ þ
Hypertelorism þ þ þ þ þ þ þ þ
Upslanting palpebral
fissures
þ þ  ND    
Long eyelashes þ þ þ ND    þ
Prominent eyes þ  þ ND þ þ  þ
Blue sclerae þ  þ ND    
Epicanthal folds  þ þ þ   þ ND
Anteverted nares þ þ þ þ þ þ  ND
Wide, low nasal bridge þ þ þ ND þ þ þ þ
Short nose þ þ þ þ þ þ þ þ
Long philtrum  þ þ þ   þ 
Triangular mouth þ þ þ þ þ þ þ ND
Thin upper lip þ þ þ þ    ND
Gingival hyperplasia þ þ þ þ þ þ þ 
Absent uvula    ND   þ ND
Cleft soft palate þ   ND    
Bilobed tongue þ þ þ    þ 
Dental anomalies þ þ þ þ þ þ þ þ
Short neck þ      þ
Micrognathia þ  þ þ    
Abnormal ear shape
and position
þ þ þ þ þ þ þ 
Skeletal Features
Mesomelia þ þ þ þ þ þ þ þ
Brachydactyly þ þ þ þ þ þ  þ
Clinodactyly þ þ þ þ   þ þ
(Continued on next page)
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Table 1. Continued
Individual
BAB4073 BAB4878 BAB5264 016462 016516 016517 017604 030526
Camptodactyly þ  ND ND   þ 
Broad thumb þ  þ þ þ þ  
Nail dysplasia þ   þ    
Bifid first and/or
second phalanges
   ND þ þ ND 
Hypoplastic phalanges þ þ þ ND þ þ þ þ
Fetal finger and/or
toe pads
   ND   þ 
Broad first toe þ þ þ þ þ þ þ þ
Scoliosis and/or
kyphosis
   þ   þ þ
Pectus anomaly þ þ  ND þ þ þ 
Urogenital Features
Sacral dimple þ  ND ND    
Cryptorchidism NA NA þ NA þ þ þ NA
Hypospadias NA NA ND NA   þ NA
Micropenis NA NA þ NA þ þ þ NA
Agenesis of the labia
minora
ND  NA þ NA NA NA ND
Small clitoris ND  NA þ NA NA NA ND
Renal anomalies    ND þ  þ 
Inguinal hernia    ND    
Other Features
Heart defects þ þ  ND    
Umbilical hernia þ þ þ ND   þ 
Seizures    ND   þ 
Hearing loss   þ þ    þ
Obstructive sleep apnea ND þ ND þ    
Absent anterior nasal
spine
   þ    þ
Increased bone density
(skull)
ND þ ND þ   þ ND
Omphalocele    ND þ   
Hepatomegaly    ND    þ
Additional clinical case reports are available in the Supplemental Data. Abbreviations are as follows: þ, present; , absent; F, female; M, male; NA, not applicable;
ND, no data; OFC, occipitofrontal circumference.(50-TGTGATCCGATTCACTGCCA-30 [reverse]). To quantify DVL1
expression, we used a qPCR assay on a reactionmixture consisting
of 200 ng of cDNA with TaqMan probes (Life Technologies)
located within the exon boundaries of exons 4 and 5
(Hs00182896_m1) and exons 14 and 15 (Hs00737028_m1). The
endogenous control probe was specific to TBP (MIM 600075), en-
coding TATA box binding protein. Expression levels were analyzed
with the SDS RQ software via the DD cycle-threshold (CT) method
(Applied Biosystems).The AmResults
Genomic and Molecular Analysis
DVL1 maps to the 1p36.3 chromosomal sub-band; its
canonical transcript contains 15 coding exons, which
together comprise 2,941 nt (RefSeq accession number
NM_004421.2), and encodes a 670-aa protein (RefSeq NP_
004412) (Figure 2A). WES identified frameshift mutationserican Journal of Human Genetics 96, 612–622, April 2, 2015 615
Figure 1. Clinical Presentation of the In-
dividuals with DRS in This Study
Subjects (clockwise from the top left)
BAB5264, 016462, 016516, 016517, and
017604 have DRS due to mutations in
DLV1 and show characteristic facial fea-
tures of frontal bossing with a high, broad
forehead, hypertelorism, a broad nasal tip,
and low-set ears.in DVL1 exon 14 (RefSeq NM_004421.2) in individuals
BAB4878 (c.1505_1517del [p.His502Profs*143] on chro-
mosome 1) and BAB5264 (c.1519del [p.Trp507Glyfs*142]
on chromosome 1). Sanger sequencing of exon 14 from
the PCR product and from PCR cloning confirmed the
presence of mutated and variant alleles in both subjects
(Figure 2B). In subject BAB4073, a missense variant
(chr1:1273426A>G) was identified by WES, but Sanger
sequencing of exon 14 failed to confirm that mutation
and instead unveiled an apparent frameshift in the
subject’s electropherogram. Further allele-specific cloning
confirmed the presence of such a frameshift involving
the missense variant detected by WES, now interpreted
as c.1570_1571delins (p.Phe524Profs*125) (Figure 2B).
This mutation was missed during the WES variant calling
most likely as a result of poor mappability. Indel calling re-
mains a challenge for massively parallel next-generation
sequencing and might reflect errors in both library prepa-
ration and algorithm artifacts.17 Complex indels, such as
the one identified in subject BAB4073 (c.1570_1571de-
lins), can be challenging to identify in exome sequencing
and can be misinterpreted as a simple base-pair substitu-
tion. Therefore, our data suggest that some frameshift
mutations might need to be confirmed with allele-specific
cloning and sequencing in addition to sequencing directly
from mixed wild-type and mutant PCR products.
Trio analysis revealed that frameshift mutations are de
novo in subjects BAB4073 and BAB4878. The mother of
BAB5264 does not carry the mutation, and the father is
unavailable. We did not detect pathogenic or predicted
pathogenic mutations in subject BAB4569 in the coding616 The American Journal of Human Genetics 96, 612–622, April 2, 2015regions of ROR2, WNT5A, or DVL1
by WES (data not shown).
Further targeted gene studies identi-
fied three unique and one recurrent
frameshift in five additional subjects.
All of these frameshifts affect exon 14
of DVL1 and are as follows: c.1505_
1517del (p.His502Profs*143) in sub-
ject 016462 (subject BAB4878 harbors
a similar frameshift), c.1508del
(p.Pro503Argfs*146) on chromosome
1 in identical twins 016516 and
016517, c.1615del (p.Ser539Alafs*
110) in subject 017604, and
c.1529del (p.Gly510Valfs*139) in sub-
ject 030526 (Figure 2B and Figure S3).Sanger sequencing of parental DNAs revealed a de novo
origin for the DVL1 mutations identified in the per-
sonal genomes from the twin pair (016516 and
016517) and from individuals 016462 and 017604. Thus,
de novo occurrence was verified in five unrelated families
for which parental DNA was available. PCR fragments
were cloned and sequenced for confirmation of reading
frames.
All the variants observed in this group of subjects with
DRS are predicted to result in a PTC located within the
last exon (15) of DVL1 (Figure 2C). Because of the location
of the predicted PTC, we hypothesized that the resulting
mutant transcript could potentially escape nonsense-
mediated decay (NMD).25 To test this hypothesis, we
performed PCR of exons 13 to 15 by using the cDNA
synthesized from isolated RNA extracted from subjects
BAB4073 and BAB5264, as well as parental samples as
wild-type controls when available. Sequencing of the RT-
PCR products revealed the presence of both wild-type
and mutated transcripts in affected individuals only (Fig-
ures 3A and 3B). Additionally, we measured the expression
levels of DVL1 by using two independent TaqMan probes
to target junctional exons 4 and 5 and exons 14 and
15 and observed no changes in the DVL1 expression be-
tween affected individuals and their parents (Figure 3C).
The expression data indicate that both alleles are ex-
pressed in affected individuals’ leukocytes and support
the hypothesis that these PTC-containing transcripts are
not degraded by NMD.
The identified mutations were not observed in publicly
available databases or in our in-house database. Analysis
DEPPDZDIX
DVL1 NM_004421.2
Exon 14
Basic 
region
Proline-rich
region
Highly conserved
 C-terminal region
A
B
BAB4073 p.Phe524Profs*125
BAB5264 p.Trp507Glyfs*142
BAB4878 p.His502Profs*143
SGTSDQDTLAPLP - - - - PGLWVRATPTSTRDPHPASRLPTRTRALAMAAAAP
 
*
*
*
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SGTSDQDTLAPLPHPAAPWPLGQGYPYQYPGPPPCPRLPTRTRALAMAAAAPBAB4073
VAAAHAVRPRLPPRGSPRPTPRPRPIQWWGGHPGDPLSGSWLPSPRN
VAAAHAVRPRLPPRGSPRPTPRPRPIQWWGGHPGDPLSGSWLPSPRN
Reference ATAPGLPPPHPTTKAYTVVGGPPGGPPVRELAAVPPELTGSRQSFQKAMGNPCEFFVDIMSGTSDQDTLAPLPHPAAPWPLGQGYPYQYPGPPPCFPPAYQDPGFSYGSGSTGSQQSE ...
...
...
...
Exon 14 Exon 15C
016517
017604
030526
016462 SGTSDQDTLAPLP - - - -
SGTSDQDTLAPLPHRLPPGLWVRATPTSTRDPHPASRLPTRTRALAMAAAAP
PGLWVRATPTSTRDPHPASRLPTRTRALAMAAAAP
...
...
...
...
VAAAHAVRPRLPPRGSPRPTPRPRPIQWWGGHPGDPLSGSWLPSPRN
VAAAHAVRPRLPPRGSPRPTPRPRPIQWWGGHPGDPLSGSWLPSPRN
VAAAHAVRPRLPPRGSPRPTPRPRPIQWWGGHPGDPLSGSWLPSPRN
VAAAHAVRPRLPPRGSPRPTPRPRPIQWWGGHPGDPLSGSWLPSPRN
*
*
*
*SGTSDQDTLAPLPHPAAPWPLGQGYPYQYPGPPPCFPPAYQDPGFSYGSGAP
SGTSDQDTLAPLPHPAAPWPLVRATPTSTRDPHPASRLPTRTRALAMAAAAP
     016462 p.His502Profs*143
016517 p.Pro503Argfs*146
030526 p.Gly510Valfs*139
017604 p.Ser539Alafs*110
GVSRVK
GVSRVK
GVSRVK
GVSRVK
GVSRVK
GVSRVK
GVSRVK
CCC CGCTGCC CC CTGGCCT CT CTGCCCCCGGCCTCTG
Mutant Allele
Reference Allele
Coordinates c.1570_1571delins
BAB4073BAB4878 BAB5264
c.1505_1517del c.1519del
CTGCCCCCTGGCCTCTG
c.1508del
016517
c.1529del
030526
c.1615del
017604
GCTGCCCCACCCGGCTGCCCCCTGGCCTCT
GCTGCCCCACCGGCTGCCCCC
GCTGCCCCACCCGGCTGCCCCC G GC CT C TG G GT C AG G G
GGCCTCTGGTCAGGG CCCTGCCCCCGCCTGCCTAA
CCTGCTTCCCGCCTGCCTACAC
C CAGCGGCGCACCGGG
CAGCGGCAGCACCGGG
Figure 2. DVL1 Variants Identified in This Study
(A) Position of known functional domains and their distribution within the DVL1 transcript. The N-terminal DIX domain is most likely
involved in regulating canonical Wnt signaling, leading to b-catenin stability;22 the PDZ domain is required for DVL1-mediated micro-
tubule stabilization23 and for regulation of signal transduction. The C-terminal DEP domain is predicted to be important for protein
interaction and most likely has a role in signal transduction; it can be found in other proteins involved in G protein signaling.24 The
approximate locations of variants identified for each affected individual all cluster within exon 14 and display the same PTC within
exon 15.
(B) Sanger sequencing of allele-specific PCR-product clones confirmed the presence of frameshift mutations in each affected individual
and revealed a C insertion in subject BAB4073. Electropherograms displaying the cloning results of both alleles for six affected individ-
uals are shown. Electropherograms for individual 016462, who carries the recurrent deletion c.1505_1517, are displayed in Figure S3.
Underlined bases are deleted in the mutant allele, and the highlighted pink base (for subject BAB4073) in the mutant allele represents
an insertion that did not exist in the reference allele.
(C) Predicted amino acid sequence with a change in the reading frame for part of exon 14 and exon 15. All variants in affected
individuals have an identical PTC within exon 15. Identical amino acids are highlighted in yellow. Asterisks indicate termination
codons.of the Exome Aggregation Consortium (ExAC) Browser
(release 0.20), a public database that provides access to
more than 61,486 unrelated subjects sequenced by WES
without confirmation by an orthogonal sequencing tech-
nology as part of distinct disease-specific and population
genetic studies, did reveal four frameshift alleles among
651 total coding mutations in DVL1. We do not predict
that any of the four suggested frameshift mutations cause
DRS because none are in exon 14. Notably, the subjects
in the ExAC collection were not generally phenotyped,
nor is it known from which disease population the study
sample was obtained. Furthermore, the ExAC Browser
includes data of heterogeneous quality, which requires
that WES-identified mutations be confirmed with an
orthogonal DNA sequencing technique that currently is
not permitted.The AmClinical Observations of Subjects with DVL1
Mutations
In general, the phenotype of individuals with DVL1muta-
tions is concordant with earlier clinical descriptions of
DRS (Table 1 and Figure 1; see Supplemental Data).2,3
Typical facial features, dental anomalies, and mesomelia
were noted in 100% of DVL1-mutation-affected individ-
uals in our study. In contrast to the DRS-affected individ-
uals with WNT5A mutations thus far reported in the
literature, 75% of DRS-affected individuals with DVL1
mutations were reported to have normal stature (above
the tenth percentile). Another possible distinguishing
feature between the two types of DRS is macrocephaly,
which was observed in 100% of individuals with DVL1
mutations in this cohort. An occipitofrontal circumfer-
ence above þ4 SDs was noted in six out of the eighterican Journal of Human Genetics 96, 612–622, April 2, 2015 617
Figure 3. mRNA Expression of Mutant Alleles
(A) Schematic representation of theDVL1 coding region. Green ovals display approximate locations of TaqMan probes Hs00182896_m1
and Hs00737028_m1. Arrows show approximate locations of primers 50-TGCTACTACGTCTTCGGGGA-30 (exon 13 fwd) and
50-TGTGATCCGATTCACTGCCA-30 (exon 15 rev), which were used to amplify cDNA of mRNA extracted from subjects’ and parents’
leukocytes.
(B) Pedigrees of subjects BAB4073 and BAB5264 and available parents for RNA isolation. Agarose gel shows a 343-bp RT-PCR band, which
was amplified with primers 50-TGCTACTACGTCTTCGGGGA-30 (exon 13 fwd) and 50-TGTGATCCGATTCACTGCCA-30 (exon 15 rev);
below, electropherograms display sequencing results of amplified cDNA. Affected individuals harbor frameshift mutations identical to
the genomic mutations identified. The variants are present in the cDNA of affected individuals but are not present in unaffected parents.
(C) Levels of DVL1 expression in leukocytes were measured by qPCR with TaqMan probes Hs00182896_m1 and Hs00737028_m1. For
evaluating relative expression of DVL1, the DDCT method was used with TBP as the endogenous control and one unaffected parent per
family as the relative control. This experiment was replicated once and showed similar results.individuals with DVL1 mutations. Except for mild intel-
lectual disability in one individual, intellectual function
was normal in all other DVL1-mutation carriers. The ma-
jority of individuals had additional congenital anomalies,
including genital hypoplasia (5/6 individuals), umbilical
hernias (4/7 individuals), heart defects (2/7 individuals),618 The American Journal of Human Genetics 96, 612–622, April 2, 2renal anomalies (2/7 individuals), and hearing loss (3/7
individuals) (Table 1). Increased skull bone density was
noted in three individuals. In addition, two subjects
presented with severe obstructive breathing problems
during sleep, and these necessitated long-term treatment
with continuous positive airway pressure and eventually015
craniofacial surgery for correction of airway obstruction
(Figures S1 and S2).Discussion
Wingless (Wg)/Wnt signaling is a highly conserved
pathway involved in cell-fate determination, including
cell proliferation, migration, and establishment of planar
cell polarity, in eukaryotic organisms. In humans, hypo-
morphic alleles and loss-of-function mutations of
WNT5A and ROR2, respectively, both of which encode
proteins involved in the non-canonical, b-catenin-inde-
pendent signaling cascade, lead to DRS and RRS, respec-
tively. Disturbing the non-canonical Wnt-5a pathway in
diverse model organisms, including mice, causes morpho-
genic defects during embryonic development.6,26,27 DRS is
hypothesized to display genetic heterogeneity given that
mutations affecting WNT5A have been previously re-
ported to account for only 1 of 24 cases.4 Recently, a report
of three new unrelated subjects with de novo mutations in
WNT5A5 confirmed that hypomorphic mutations in this
gene are an important cause of DRS, but most subjects
clinically diagnosed with Robinow syndrome do not
have mutations in genes with a known association with
the disease. Therefore, it is possible that the majority of
the affected subjects will have mutations in distinct genes
potentially involved in the same signaling pathway.3
In agreement with this hypothesis, we report eight DRS-
affected subjects carrying frameshift mutations in exon
14 of DVL1.
In general, the phenotype of the herein-studied individ-
uals with DVL1 mutations is concordant with earlier clin-
ical descriptions of DRS (Table 1 and Figure 1; see Supple-
mental Data).2,3 However, we suggest macrocephaly and
absence of short stature as potential genotype-phenotype
correlations for subjects with DVL1-associated Robinow
syndrome. Individuals with WNT5A mutations can have
macrocephaly at birth, but head circumference generally
undergoes a postnatal progression to normocephaly.1,4,5
Even though Robinow syndrome is generally considered
a ‘‘typical gestalt’’ diagnosis, facial features can become
less clear during puberty and adulthood, and the diagnosis
can be less obvious in individuals with normal stature18
(Figures S1 and S2). Therefore, the availability of another
gene test for DRS could help confirm this clinical diag-
nosis. Furthermore, given the mappability challenges of
the frameshift mutations identified herein, future clinical
application might benefit from the use of traditional
Sanger sequencing as a first approach for clinical diagnosis
in individuals suspected of having DRS. Moreover, if a clin-
ical diagnosis is suspected in a subject who previously had
WES testing, then it might be prudent to examine the raw
data obtained at the DVL1 locus.
DVL is a segment polarity gene (dsh) originally discov-
ered in Drosophila, where it mediates Wg signaling trans-
duction of patterning information in multiple tissuesThe Amduring the developmental processes, including axial
patterning of legs and wings in adults.28,29 In the devel-
oping Drosophila embryo, lack of dsh results in functional
defects similar to those observed inwgmutants; further ex-
periments revealed that Dsh functions in the reception or
interpretation of the Wg signal.29,30 Three dsh homologs,
DVL1, DVL2 (MIM 602151), and DVL3 (MIM 601368),
have been identified in mammals, including humans.31
Experimental data indicate that there could be functional
redundancy among Dvl proteins,32,33 but individual spe-
cific roles for each of these proteins are also being pro-
posed.34 These observations are in agreement with a
recently published mosaic genetic screen of lethal muta-
tions on theDrosophilaX chromosome; the screen revealed
that fly genes with more than one human homolog are
more likely to be associated with human syndromes than
are fly genes with a single homolog, potentially indicating
duplication and further specialization during evolution.35
Human DVL proteins, DVL1, DVL2, and DVL3, share
59%–67% of amino acid sequence identity, and the
corresponding mouse orthologs show >95% of amino
acid sequence identity.31 Mouse Dvl1 was shown to be
ubiquitously expressed in adult tissues, particularly in the
brain and testes.36 However, Dvl1-null mice do not present
with developmental defects; instead, they show abnormal
social behavior, such as a lack of whisker trimming, poor
nest building, and decreased huddling during sleep, in
addition to diminished sensorimotor gating.37 These data
suggest that Dvl1 might contribute to the modulation of
social behaviors in mammals; however, it is unclear what
might constitute human ‘‘homologous’’ instinctual behav-
iors that onemight screen for in our subjects. Furthermore,
there is no evidence of altered behavior traits associated
with DRS; in fact, most individuals from our cohort
performwell in terms of social integration and functioning
(see Supplemental Data), supporting the contention that
the mechanism of DRS caused by mutations in DVL1 is
not due to loss of function.
In our study, we observed a total of six frameshift muta-
tions, five of which were confirmed to be de novo. Analysis
of the ExAC Browser revealed the presence of four frame-
shift variants affecting DVL1, but the relevance of such
findings forDRS is unknownbecause (1)we cannot confirm
the ExAC Browser mutations by Sanger sequencing, (2) we
do not have phenotypic information on those particular
subjects, and (3) none of these mutations affect exon 14
of DVL1, which might suggest that frameshift mutations
elsewhere in DVL1might not cause DRS.
Remarkably, all variants observed in this cohort are pre-
dicted to produce a PTC that maps within the last exon of
DVL1 and are predicted to escape NMD; this hypothesis is
supported by our mRNA studies. NMD is a conserved post-
transcriptional surveillance system that is intended to
degrade transcripts that contain a PTC and thus eliminate
abnormal transcripts (reviewed in Conti et al.38 and Popp
et al.39); evidence of such NMD was not observed in our
subjects. In the resulting predicted altered proteins, 22erican Journal of Human Genetics 96, 612–622, April 2, 2015 619
amino acids from the C terminus will be removed, but
other highly conserved functional domains, i.e., DIX,
PDZ, and DEP, will be preserved. The exact function of
the DVL1 C terminus is unknown, but the last 35 amino
acids have been shown to be conserved among all verte-
brate Dvl proteins.31 Intriguingly, in all six mutations re-
ported here, the frameshift leads to the same open reading
frame, which is predicted to generate a PTCwithin the cod-
ing region of exon 15. This most likely produces a novel
DVL1 C-terminal truncation that retains 109 amino acids
shared by all eight subjects (Figure 2C). Further studies
are required to investigate whether DRS-associated muta-
tions in exon 14 of DVL1 produce a protein with residual
activity that competes with the wild-type protein and dis-
turbs its function (antemorph) or whether the novel C-ter-
minal domain performs a new, unpredicted biological role
(neomorph). In any case, a dominant-negative or gain-of-
function altered protein is predicted to contribute to the
dominant disease trait.
Nonsense mutations within the last 50 base pairs of the
penultimate exon and within the last exon are hypothe-
sized to escape NMD, leading to the synthesis of C-termi-
nally truncated proteins. These truncated proteins can
result in diseases as a result of dominant-negative or
gain-of-function mechanisms.40 Importantly, a mutant
transcript being subjected to NMD or escaping NMD can
lead to distinct disease-inheritance patterns and variable
clinical severity,15,25 examples of which include mutations
in ROR2: recessive ROR2 mutations cause RRS, whereas
dominant ROR2 mutations cause BDB1. SOX10 (MIM
602229) mutations also cause one of two distinct domi-
nant diseases, Waardenburg syndrome (MIM 602229) or
PCWH (peripheral demyelinating neuropathy, central dys-
myelination, Waardenburg syndrome, and Hirschsprung
disease [MIM 609136]), depending on whether the tran-
script containing the PTC is subjected to or escapes
NMD, respectively.41 Recently, de novo truncation in the
single-exon gene AHDC1 (MIM 615790) was found in sub-
jects with a new neurological disorder, Xia-Gibbs syn-
drome (MIM 615829), consisting of developmental delay,
hypotonia, mild dysmorphic features, sleep apnea, and
other symptoms. Single-exon genes all escape NMD. In
aggregate, these observations suggest that the interpreta-
tion of the biological effects of nonsense and frameshift
alleles can be difficult to predict and most certainly do
not always cause loss of function, but rather can be null
(haploinsufficiency), hypomorphic, antemorphic, or neo-
morphic. The presence of frameshift or nonsense muta-
tions that allow transcripts to escape NMD can provide
an improved set of tools for identifying mutations associ-
ated with human disease.41–43
Both canonical and non-canonical Wnt signaling,
including via Wnt-5a, have been demonstrated to be
important effectors of bone mass in humans and animal
models.44 Wnt signaling increases osteoblastogenesis,
which increases bone mass. As examples, loss-of-function
mutations in AMER1 (MIM 300647), a gene that represses620 The American Journal of Human Genetics 96, 612–622, April 2, 2canonical Wnt signaling, results in the increased-bone-
mass phenotype of osteopathia striata with cranial sclerosis
(MIM 300373),45 whereas loss-of-function mutations
in LRP5 (MIM 603506), which normally transduces
canonical Wnt signaling, results in the decreased-bone-
mass phenotype of osteoporosis-pseudoglioma syndrome
(MIM 259770).46 Given the increased cranial density seen
in a few of our subjects, further investigation for any poten-
tial role of DVL1 in regulating bone density is warranted.
No constitutional diseases have yet been associated with
specific mutations in human DVL genes. Copy-number
alteration spanning 17p13.1, specifically deletion copy-
number variation (CNV) that includes DVL2, can lead
to intellectual disability and microcephaly.47 DVL1 has
been proposed as a candidate gene for the cardiovascular
malformations and cardiomyopathy phenotypes observed
in individuals with the 1p36 deletion syndrome (MIM
607872).48 Nonetheless, this deletion-CNV syndrome
does not include the typical facial and skeletal features
observed inRobinowsyndrome, supporting the contention
that haploinsufficiency is not themechanism for disease in
DRS caused by DVL1 mutations. Loss-of-function muta-
tions in Dvl1/ mice cause a relatively mild phenotype
consisting of behavioral problems. This contrasts sharply
with the severe morphological defects observed in mice
with null mutations in Wnt5a or Ror2. These observations
inmice support our hypothesis that truncatedDVL1 in sub-
jectswithDRS is probably not due to loss-of-functionmuta-
tions. Our data suggest that mutations that lead to the for-
mation of truncated DVL1, which has a distinct terminus
due to specific1 frameshifting variants in the penultimate
exon, can disrupt the Wnt-5a-ROR2 pathway and cause
overlapping clinical phenotypes.We therefore hypothesize
thatWNT5A, ROR2, andDVL1, similar to their orthologs in
other organisms, act in the same pathway in humans.Accession Numbers
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